CTLT רווח למניה בשנים עשר החודשים האחרונים Catalent Pharma Solutions

The rolling net income per share indicates current trend resilience, with the metric standing at -2.24. Catalent, Inc. (CTLT) is actively automating sterile lines for the production of GLP-1 drugs. A broad network of plants and thousands of clients minimize the risks of program cancellations. However, the moderate cyclicality of the CDMO sector makes service procurement dependent on the cost of capital and the pace of new drug launches.

The capacity utilization efficiency of Catalent, Inc. (CTLT) fill-finish operations for biologics is directly reflected in the company's TTM net income per share dynamics. This indicator aggregates net income over the last four quarters, dividing it by the total number of shares. Such a methodology neutralizes seasonality, demonstrating the actual yield per share. The upward trend confirms strict adherence to GMP standards and the loyalty of major clients. This stable trend testifies to the financial resilience of the CDMO business.